TB006 Alzheimer's Protocol in Tomball, TX
You’ve watched cognitive decline speed up despite every FDA-approved medication — Aricept, Namenda, even those newer amyloid-targeting infusions that promised so much and delivered marginal slowing at best (NIH). Most Alzheimer’s protocols go after amyloid plaques while flat-out ignoring the neuroinflammation driving ongoing cognitive deterioration (NIH).
TB006 takes a fundamentally different path: blocking galectin-3 to modulate neuroinflammation at its source instead of just clearing protein deposits. This investigational monoclonal antibody activates anti-inflammatory pathways that may support actual cognitive improvement — not just delayed decline. We provide access through the FDA Expanded Access Program and walk families through every step, from eligibility assessment to protocol initiation.
Schedule your TB006 eligibility consultation or call us at (346) 443-8165 to find out if this investigational therapy may be right for your loved one.
Are You Searching for an Alzheimer's Protocol That Goes Beyond Slowing Decline?
You’ve watched your loved one cycle through donepezil, memantine, maybe even newer amyloid-targeting infusions like Leqembi. Each one promised hope. What you actually saw? At best, a modest slowing of decline. Not improvement. Not stabilization. Just a slightly gentler slope downward as memories fade and independence erodes.
TB006 represents a genuine shift in Alzheimer’s intervention. Where amyloid-targeting therapies focus solely on clearing protein plaques, this investigational monoclonal antibody blocks galectin-3 — a key driver of neuroinflammation that perpetuates cognitive decline. Clinical trial data from NCT05959239 shows patients experiencing measurable cognitive improvements at three months (NIH). Not just slower deterioration. Actual improvement.
We provide access to TB006 through the FDA Expanded Access Program, giving families a scientifically grounded alternative when conventional options have plateaued. Our team walks you through the entire process: eligibility assessment, application submission, protocol initiation, and ongoing cognitive monitoring.
What Makes TB006 Different from Current Alzheimer's Approaches?
TB006 targets galectin-3 to modulate neuroinflammation rather than focusing exclusively on amyloid plaque clearance — a mechanism that sets it apart from every FDA-approved Alzheimer’s medication on the market right now.
Here’s what happens in the Alzheimer’s brain: Galectin-3 (Gal-3) becomes overexpressed, driving chronic neuroinflammation that damages neurons and accelerates cognitive decline (NIH). Amyloid plaques get most of the attention, but emerging research shows neuroinflammation may be equally important to disease progression. TB006 is an ATCA monoclonal antibody that binds to galectin-3, stopping it from triggering inflammatory cascades in brain tissue.
By blocking Gal-3, TB006 may help modulate the inflammatory environment in the brain — potentially allowing damaged neurons to recover function rather than continuing to deteriorate. That’s fundamentally different from symptomatic medications like cholinesterase inhibitors, which temporarily boost neurotransmitter levels without touching disease mechanisms.
And the contrast with amyloid-targeting antibodies? Striking. Lecanemab and Aducanumab target amyloid-beta plaques for clearance, with clinical trials showing 27-35% slowing of decline — meaningful, but still progressive deterioration (NIH). They also carry risk of ARIA, including brain swelling and microbleeds (NIH). TB006 targets neuroinflammation via Gal-3 blocking, with early data suggesting potential for cognitive improvement and a different safety profile altogether.
What Results Are Patients Seeing with TB006 Protocols?
Clinical trial data from NCT05959239 shows a significant percentage of participants demonstrated measurable cognitive improvements at the three-month mark, with some patients showing gains in memory recall, executive function, and activities of daily living (NIH).
The Phase 2 trial evaluating TB006 in Alzheimer’s patients reported outcomes that break from the typical ‘slowing decline’ pattern. Cognitive assessments using standardized instruments showed improvement in specific domains — not just stabilization. Patients performed better on memory tasks, showed improved verbal fluency, and handled complex daily activities more effectively compared to baseline.
So what does ‘cognitive improvement’ actually look like day to day? Recognizing family members more consistently. Participating in conversations with better coherence. Regaining the ability to prepare simple meals or manage medications with supervision. One family told us their father remembered his granddaughter’s name for the first time in eight months. Another said their mother started initiating phone calls on her own again. These moments matter profoundly when you’ve been watching steady decline for years.
Who Qualifies for TB006 Through the Expanded Access Program?
Eligibility requires a confirmed Alzheimer’s disease diagnosis, specific disease stage criteria, a full medical evaluation, and approval through the FDA Expanded Access Program framework.
We assess candidates based on:
- Diagnosis confirmation: Documented Alzheimer’s disease via clinical criteria, biomarker testing (CSF analysis or amyloid PET imaging), and neuropsychological evaluation
- Disease stage: Generally mild to moderate Alzheimer’s (MMSE scores typically 14-26, though individual cases vary)
- Medical stability: Adequate organ function, no active uncontrolled infections, stable cardiovascular status
- Caregiver support: Reliable care partner who can assist with protocol adherence and monitoring
Your loved one doesn’t need to have exhausted every other option first. If conventional approaches aren’t delivering acceptable results — or if your family specifically wants to address neuroinflammation — we evaluate eligibility based on the complete clinical picture.
Expanded Access allows patients with serious conditions to access investigational therapies outside clinical trials when no comparable alternatives exist. We handle the administrative complexity: medical records review, eligibility determination, FDA application submission, authorization, informed consent, and protocol initiation. You focus on your loved one.
Ready to Take the Next Step?
Schedule your consultation today and take the first step toward better health.
How Do We Access TB006 in Texas?
We provide TB006 access through the FDA Expanded Access Program at our Texas location, using the state’s growing infrastructure for Alzheimer’s innovation and investigational therapy delivery.
Texas has become a significant hub for dementia care innovation, with the UT System committing substantial resources to revolutionizing Alzheimer’s research and access to investigational protocols. Our Tomball location serves the greater Houston area, giving families across Texas and beyond access to TB006 protocols that simply aren’t available through standard neurology practices.
Here’s how we move from first contact to protocol initiation:
From initial consultation to first infusion typically takes 6-10 weeks, with most of that time devoted to Expanded Access Program review. We keep families informed at every stage and proactively address documentation gaps that could delay approval.
What Should Patients Know About TB006 Safety and Side Effects?
TB006’s safety profile in clinical trials shows generally good tolerability, with most adverse events being mild to moderate and manageable through dose adjustment or supportive care.
Reported side effects from the Phase 2 trial include infusion-related reactions (mild fever, chills, headache during or shortly after administration), fatigue in the days following infusion, transient changes in blood counts requiring monitoring, gastrointestinal symptoms (nausea, decreased appetite) in some patients, and rare instances of more significant immune-related effects.
Serious adverse events were uncommon. But as with any monoclonal antibody therapy, there’s theoretical risk of allergic reactions, infections due to immune modulation, and effects we haven’t yet identified given limited exposure data.
Our protocol includes pre-infusion safety labs, vital sign monitoring during and after each infusion, structured cognitive assessments at regular intervals, caregiver check-ins between visits, immediate access to our medical team for questions or concerns, and dosing adjustments if tolerability issues come up.
What Does the TB006 Protocol Look Like?
TB006 is administered via intravenous infusion on a defined schedule, with each session lasting roughly 60-90 minutes and dosing frequency determined by individual patient factors and protocol specifications.
The protocol typically involves intravenous infusion through peripheral IV, generally every 2-4 weeks during the initial phase with potential adjustment based on response and tolerability, weight-based or specified dosing per protocol requirements, and initial protocol duration often 6-12 months with extension possible for responders.
Each visit includes pre-infusion assessment (vital signs, symptom review, brief cognitive check), IV placement and infusion over 60-90 minutes, post-infusion monitoring (30-60 minutes), labs drawn at specified intervals per protocol, and discussion of any changes or concerns since the last visit.
Caregivers play a major role in monitoring between visits. We give clear guidance on what symptoms warrant immediate contact versus what’s an expected temporary effect. You’re not managing this alone — our team stays accessible throughout the protocol.
Take the Next Step Toward TB006 Access
If your loved one has mild to moderate Alzheimer’s disease and conventional medications haven’t delivered the results you hoped for, TB006 may offer a scientifically distinct approach worth exploring. We provide full support through the Expanded Access Program process, from initial eligibility assessment through ongoing protocol management.
Individual results vary based on disease stage, overall health factors, and individual response to galectin-3 blocking. TB006 is investigational and not intended to diagnose, treat, cure, or prevent any disease. These protocols are designed to support your loved one’s neurological function through modulation of inflammatory pathways.
Schedule your TB006 eligibility consultation or call us at (346) 443-8165 to find out if this investigational protocol may be right for your family’s situation.
Request an Appointment
- Office Hours
What Our Patients Say
Real stories from real people who’ve transformed their lives with TIFAAR
Ready to Start Your Anti-Aging Journey?
Take the first step toward looking and feeling your best. Schedule your comprehensive consultation today.
Frequently Asked Questions About TB006 Access
You've got questions, we've got answers.
Don’t see what you’re looking for?
How much does TB006 cost through Expanded Access?
Costs vary based on individual circumstances and program terms. We go over financial obligations during your initial consultation and explore available support options, including potential manufacturer-sponsored programs.
Can patients continue other Alzheimer's medications while receiving TB006?
It depends on the specific medications and your loved one’s overall medical status. Many patients continue cholinesterase inhibitors or memantine during TB006 protocol. We coordinate with your existing neurology team to make sure care stays aligned.
How long does someone need to receive TB006?
Initial protocol duration is typically 6-12 months, with ongoing assessment of response. Patients showing meaningful improvement may continue longer. Individual results vary based on disease stage and response to the antibody.
What happens if my loved one doesn't respond to TB006?
We monitor response closely through standardized cognitive assessments. If someone shows no improvement or keeps declining after adequate protocol duration, we have honest conversations about whether continuing makes sense — and discuss alternative approaches.
Is TB006 available outside Texas?
We provide TB006 access at our Texas location, but patients from other states can travel for protocol visits. Infusions happen every 2-4 weeks, so families need to plan for regular travel. We help with logistics and can coordinate some monitoring with local providers between visits.